In addition to its classic AR pathway inhibition, enzalutamide has also been found to exert a mechanism of prostate cancer inhibition through non-AR inhibition [45] or combine treatment [46, 47], which further strengthens its position as a cornerstone of prostate cancer treatment [48]. This evidence concerns the gene AR and prostate carcinoma.